Evidence map›Paper›PMID 29556019›Full record

ArticleLeukemia2018

High-throughput sequencing of nodal marginal zone lymphomas identifies recurrent BRAF mutations.

V Pillonel, D Juskevicius, C K Y Ng, A Bodmer, A Zettl, D Jucker, S Dirnhofer, A Tzankov

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 2 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Diagnostic and prognostic molecular pathology of lymphoid malignancies.Virchows Archiv : an international journal of pathology · 2024
    Review
  15. Article
  16. Article
  17. Article
  18. Follicular lymphoma and marginal zone lymphoma: how many diseases?Virchows Archiv : an international journal of pathology · 2023
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

V PillonelInstitute of Pathology and Medical Genetics, University Hospital Basel, University of Basel, Basel, Switzerland.
D JuskeviciusInstitute of Pathology and Medical Genetics, University Hospital Basel, University of Basel, Basel, Switzerland.
C K Y NgInstitute of Pathology and Medical Genetics, University Hospital Basel, University of Basel, Basel, Switzerland.ORCID http://orcid.org/0000-0002-6100-0026
A BodmerInstitute of Pathology, Cantonal Hospital Baselland, Liestal, Switzerland.
A ZettlPathology, Viollier AG, Allschwil, Switzerland.
D JuckerInstitute of Pathology and Medical Genetics, University Hospital Basel, University of Basel, Basel, Switzerland.
S DirnhoferInstitute of Pathology and Medical Genetics, University Hospital Basel, University of Basel, Basel, Switzerland.
A TzankovInstitute of Pathology and Medical Genetics, University Hospital Basel, University of Basel, Basel, Switzerland. alexandar.tzankov@usb.ch.ORCID http://orcid.org/0000-0002-1100-3819
University of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nodal marginal zone lymphoma (NMZL) is a rare small B-cell lymphoma lacking disease-defining phenotype and precise diagnostic markers. To better understand the mutational landscape of NMZL, particularly in comparison to other nodal small B-cell lymphomas, we performed whole-exome sequencing, targeted high-throughput sequencing, and array-comparative genomic hybridization on a retrospective series. Our study identified for the first time recurrent, diagnostically useful, and potentially therapeutically relevant BRAF mutations in NMZL. Sets of somatic mutations that could help to discriminate NMZL from other closely related small B-cell lymphomas were uncovered and tested on unclassifiable small B-cell lymphoma cases, in which clinical, morphological, and phenotypical features were equivocal. Application of targeted gene panel sequencing gave at many occasions valuable clues for more specific classification.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorFemaleHigh-Throughput Nucleotide SequencingHumansLymphoma, B-Cell, Marginal ZoneMaleMiddle AgedMutationNeoplasm Recurrence, LocalPhenotypeProto-Oncogene Proteins B-rafRetrospective StudiesBiomarkers, TumorBRAF protein, humanProto-Oncogene Proteins B-raf

Identifiers

PMID29556019
PMCPMC6224405
OpenAlexW2792489326

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.